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Introduction
Identifying a nutritional cause of cardiovascular disease
(CVD),anutrientthatcouldbemanipulatedtoreverseCVD
morbidityandmortality,wouldbefindingtheHolyGrailof
nutrition and CV science. Cardiovascular researchers and
public policy advocates have long labeled dietary sodium
as this nutrient, what they consider the primary dietary fac-
tor in the pathogenesis of high blood pressure (BP) and
subsequent CVD, despite the lack of valid scientific data
to bear this out [1]. While Mimran et al. [2] promulgate
this claim in their commentary in this issue, they fail to
acknowledge the defects in their supporting evidence or
the more carefully derived evidence demonstrating that di-
etary sodium holds no more than an ancillary, if any, role
in the development of cardiovascular or renal disease in the
general population. That assessment is not to suggest that
the management of many patients with chronic kidney dis-
ease, congestive heart failure and liver disease among other
specific medical conditions should not include sodium re-
striction. In these highly selected populations, though, the
need for or, indeed, the benefits of reduced sodium intake
are not universal either.
The short history of the race
For over a century, the medical sciences have explored the
relationship between salt and BP [3]. In the 50 years that
ensued investigators began to focus on sodium balance and
volume regulation as a root cause. Clinical studies purport-
ing to directly examine the salt/BP relationship emerged
in the 1940s and continued over the next several decades.
It was not until the 1980s, however, that such studies em-
ployed rigorous scientific standards, i.e. randomization of
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the interventions and longitudinal follow-up of larger pop-
ulations with measures of sodium intake and health out-
comes. Only in the last 10 years have intervention trials
appropriately controlled for other factors that can influence
the BP effects of sodium. Despite a century of research, the
final and most important piece of scientific evidence has
never been produced: indisputable data that lower sodium
intake reduces all-cause mortality, the goal of all universal
health policies.
The revisionist history of the race
My own interest in the BP effects of salt began with
one hypertensive patient seen in 1976 [4]. Subsequent
observational studies prompted by that patient’s mineral
metabolism disturbances catapulted my laboratory into the
maelstrom surrounding sodium’s purported effects on BP
that existed even then [5]. Those efforts early on lead to
our identification of another dietary pattern potentially
more important: fruits, vegetables and dairy [6], which
became the basis of the DASH diet and the US Food Guide
Pyramid. Over the next 20 years our and others’ work
revealed critical weaknesses in the data used to support
sodium restriction for the population-at-large. Evidence
and reasoning defects identified then apply today to the
commentary of Mimran et al.[ 2 ] .
First, until the mid-1980s virtually all the animal studies
of salt’s BP effects and other cardiovascular outcomes em-
ployed levels of dietary sodium or metabolic perturbations
(nephrectomy, steroid injection, inbreeding, etc.) that have
no relevance to the human condition [7,8]. Subsequently,
as our earlier observational studies in humans suggested
[6,9], controlling animal studies for adequate mineral in-
take negated salt’s effects in diverse animal models of hy-
pertension [10,11] and cardiovascular sequelae. There is no
debate that excessive amounts of sodium in laboratory an-
imals, from rats [2] to chimpanzees [12], can impact CVD
riskfactors.However,applyingthosefindingsdirectlytothe
issue of human CVD risk and, most importantly, all-cause
mortality and public health policy is more than a stretch.
Second,manyoftheearlyobservationalstudies[7,13,14]
and intervention trials [8,15] inadequately documented
dietary sodium intake and that of other nutritional fac-
tors and minerals that are known to influence BP. For
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example, the randomized trials of MacGregor and col-
leagues that routinely demonstrated an effect of salt re-
striction or supplementation in humans were set up by si-
multaneously restricting dietary potassium as reflected by
urinary potassium excretion measures [16,17]. This limita-
tion of MacGregor’s trials of sodium effects on BP is criti-
cal because the presence of adequate dietary potassium has
been shown to blunt sodium sensitivity [18] and, of greater
importance, reduce stroke risk [19]. Finally, in 1988, the
Intersalt Study provided excellent measures of both 24-h
urinary sodium and BP in over 10 000 subjects in 32 coun-
tries around the world [20]. Intersalt demonstrated that its
two primary outcome measures were negative: there was
no relationship between dietary sodium and mean BP or
the prevalence of hypertension within a site or across all
sites.
Third, the concept that sodium restriction would bene-
fit the entire population was dealt a lasting blow by Luft
et al. beginning in the late 1970s [21,22]. In a series of
controlled interventions, they demonstrated that the BP re-
sponseofbothnormalandhypertensiveindividualstolower
dietary sodium intake was heterogeneous, i.e. almost equal
portions of the population experienced an increase or a de-
crease in BP. This finding of a heterogeneous response to
sodium restriction has now been replicated numerous times
[23]. Thus, the mantra for population-wide salt restriction,
as exemplified by Mimran et al. [2], carries potential risk.
Specifically, some portion of the ‘non-salt sensitive’ pop-
ulation, normotensive or hypertensive, will experience ele-
vations in BP.
Fourth, until recently, most experts assumed that lower-
ing BP equated with lowering CVD risk, which would be
reflected in reduced all-cause mortality. Still prevalent to-
day [24] and advanced by champions of population-wide
sodium restriction, that assumption is no longer defensible
as other experts have indicated [25]. We learned from the
NIH-sponsoredALLHATTrialthathowBPisloweredmat-
ters in terms of reducing CVD and all-cause mortality. In
ALLHAT, one of the antihypertensive medications that ef-
fectivelyloweredBPwasactuallyassociatedwithincreased
risk of CVD and death [26]. In a landmark study, Alderman
et al. [27] published data from an NIH-funded trial where
high-risk participants were provided standard nutritional
advice including dietary recommendations thought to im-
prove favorable health outcomes. This study indicated that
lower sodium intakes were associated with an increase in
myocardial infarction and CVD-related deaths. This find-
ing, suggesting a risk, has now been observed in a variety
of databases [28–30], including large federally supported
databases with longitudinal data reflecting the general pop-
ulation. Several have found no relationship in either direc-
tion, thus no benefit or harm [30]. A few have identified
an all-cause mortality benefit of lower dietary sodium in
subgroups [31], but not across the general population [32].
Have the bookies skewed the odds?
After 100 years of research and still no credible evidence
that reduced salt intake imparts a net balance of cardiovas-
cular benefits such that all-cause mortality is lowered, why
are some investigators continuing their mission to codify




to turn a phantom entry into a dark horse in their race for
the Holy Grail, the nutritional cause of CVD. Playing with
the data, or in this case the ‘odds’, has its roots in a se-
ries of often-cited publications. The advocates, or here the
‘bookies’, have stacked the odds by repeatedly citing com-
promised reports, stacked one upon another, to build their
argument that salt is the odds-on favorite.
We must recognize that the wealth of animal studies are
interesting in exploring mechanisms, but are immaterial to
the only piece of evidence that should matter at this stage:
Do humans live longer when they consume less sodium?
Themeta-analysesofhumantrialstypicallycitedtosupport
the push for universal restriction are helpful, but their accu-
racy is in question. As noted above, if the randomized trials
that showed the biggest effect were not properly designed
or the data were not fully reported, they would compromise
thevalidityofanymeta-analysisinwhichtheyareincluded.
Remove those studies from the meta-analyses and any di-
etary sodium effect would be markedly different [35,36]
and likely of no significance.
The overestimated effect is important because numer-
ous salt restriction proponents, i.e. bookies, have published
quantitativeestimatesoflivesthatwouldbesavedifsodium
intake were reduced [37]. But when manipulating the data
or odds is taken into consideration, the value of these es-
timates is zero. If the calculations begin with an incorrect
number,thenthereisnoaccuratebasisfromwhichtoassess
the public health impact.
A better estimate can be made from the DASH-Sodium
trial [38], as it controlled for nutritional and demographic
variables that might influence sodium’s effects on BP. Yet,
here again the bookies have skewed the odds, greatly in-
flating and selectively reporting the salt reduction effects
[39]. It is this interpretation that Mimran et al. [2] and
Dickinson et al. [34] use to bolster their case for universal
dietary sodium restriction, and, more importantly, that is
the basis of the argument that sodium restriction will lower
BP in normotensive persons.
Why is it inflated? How did the bookies stack the
odds? Simply put, the DASH-Sodium cohort was heav-
ily weighted toward typically salt-sensitive subjects (e.g.
African American, hypertensive, overweight). The subjects
were‘stacked’toamplifyanypotentialimpactofsodiumre-
striction. Normally that would be acceptable, provided that
the appropriate multivariate analysis was employed to fac-
toroutknownconfoundingcharacteristics;however,despite
numerous [39,40] and public requests for this analysis, it
has never been published. Thus, the results of even the best
designed intervention trial have been overstated and then
incorporated into estimates of the odds by these bookies.
The home stretch
No matter how much data Mimran et al. [2] or others
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non-pressure effects of dietary sodium (LVH, albuminuria,
etc.), a substantive body of data proving that lower salt in-
take will reduce all-cause mortality, that humans will live
longer, healthier lives, does not exist. We have at least a
dozen observational studies [30,41,42] that shed some light
on that question, and while none can provide the defini-
tive answer, collectively they raise the distinct possibility
we would cause more harm than good. In the end, public
health policy must rest on health outcomes. Do humans
live longer? Those are the odds we should primarily be
concerned with, not surrogate end-points.
Even in this area, the bookies have skewed the odds, im-
peding efforts to determine the magnitude of the risk. In
their report of long-term CVD outcomes in TOHP I and II
participants, Cook et al. [42] portray the data as showing
that instruction in a lower sodium diet 10–15 years previ-
ous was associated with a reduction in all-cause mortality.
Careful reading, however, reveals that their conclusion was
based on multiple comparisons that did not demonstrate a
significant reduction in all-cause mortality. They carry this
misconstruction into the discussion, claiming these non-
significant results ‘reinforce’ the need to lower sodium in
the general population. This is simply untrue—TOHP I
and II did not study a normal population; improvements in
CVD outcomes, while possibly significant, did not trans-
late into a significant reduction in mortality. This criti-
cal limitation is acknowledged where the authors state,
‘The magnitude of risk reduction in this full intention to
treat analysis...there was a 20% lower mortality among
those in the sodium reduction group (0.80, 0.51 to 1.26,
P = 0.34)’—not a significant finding. Equally important,
nothingisknownabouttheactualdietsoftheseparticipants
in these poststudy years. Their classification of sodium in-
take was simply based on the initial randomization more
than 10 years earlier.
Contrasting the TOHP I and II results is the recent re-
port from the Rotterdam Study [43], which provided lon-
gitudinal health outcomes data based on the most accurate
measure of dietary sodium, urinary excretion of the elec-
trolyte.Thatcase-cohortstudyfromtheoriginalpopulation
of almost 8000 adults >55 years did not find an association
between sodium intake and either CVD or all-cause mor-
tality, although there was a suggestion of risk from a lower
sodium diet. Table 3 of that report indicates that the risk
was not in the subjects ‘free of CVD’. Follow-up commu-
niqu´ es (personal communication) with one of the authors
did confirm that subjects with a prior CVD history had a
significant 27% greater risk of CVD mortality and a bor-
derline significant 17% increase in all-cause mortality on
lower sodium intakes.
In fact, the TOHP I and II data based on the appropri-
ate adjusted ‘intention to treat’ analysis and the Rotterdam
findings are consistent with the comprehensive analysis
of published papers addressing the mortality issue with
sodium restriction. Alderman provided this assessment in
his 2007 Presidential Address to the International Society
of Hypertension [44]. He noted that there were 10 publica-
tions in populations with sodium intake within the normal
range (the TOHP and Rotterdam data had not been pub-
lished at the time of his writing). These reports all provided
health outcomes data and estimates of sodium intake, and
none showed any consistent evidence of lower mortality
with lower sodium. Quite the contrary, they strongly sug-
gest harm, i.e. increased deaths with lower sodium. Table
2 of that paper notes that the 10 studies comprise over
131 000 subjects, 1.2 million years of patient observations
and almost 7800 outcome events—hardly small numbers,
making the odds remote that they are misleading. The addi-
tion of TOHP and Rotterdam data simply strengthens those
odds.
And the winner is...
I believe science is the winner. Our patients and the
entire population deserve public health policies based
on reproducible scientific data that assure safety and
efficacy. Medical science, particularly the science of
public health, has not always adhered to that standard. For
example, millions of women worldwide were exposed to
significant CVD and cancer risks for decades because of
the broad endorsement of hormone replacement therapy,
and hundreds of millions of individuals have been exposed
to the cardiovascular risk of trans-fats in the diet. These
public health fiascos could have been prevented by feasible
trials at the outset to document the safety of the policies
that perpetrated these outcomes.
The same is true for universal dietary sodium reduction.
We need to do the study. The pilot has been done, TOHP II.
We simply need to replicate that basic study design with
good measures of sodium intake as we learned how to
do in the Intersalt Study. Finally, we need to assess both
CVD and all-cause mortality. We know how to do that. It
is time, well past time, to answer the ‘lower sodium/higher
life expectancy’ question. I cannot imagine any respon-
sible scientist betting against the importance of answer-
ing this question. Some bookies might though because it
will likely show that their dark horse is merely a phantom
entry.
Today’s better bet
A better bet to lower CVD risk and improve all-cause mor-
tality in persons at risk of hypertensive heart disease would
be to rely on the proven lifestyle workhorses: weight con-
trol, moderate alcohol intake, smoking cessation and im-
proved diet quality. The benefits of the latter were recently
reinforced by data from over 88 000 women in the Nurses’
HealthStudy[45].Inthatlargecohortfollowedfor24years,
improved diet quality, defined primarily by greater intake
of fruits, vegetables and low-fat dairy foods (DASH diet),
was associated with a 27% reduction in total CHD and a
34% reduction in fatal CHD. Total stroke incidence was
reduced 17%. All these improvements in health outcomes
were highly significant. Not surprising to this betting in-
vestigator, sodium intake did not vary statistically across
the quintiles of the DASH profile. Of even greater signifi-
cance, the impact of the DASH diet was most pronounced
in those women at greatest CVD risk: smokers, overweight,
hypertensive and the sedentary.2136 D. A. McCarron
As scientists and the bookmakers, who set the odds
for our patients’ benefits, we need to focus on these
‘thoroughbreds’ of lifestyle factors. Betting on phantom
entries, such as sodium restriction, risks more than health-
care currency; it may also reduce the quality and the length
of life.
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